The ARIH2 Knockout A-549 Polyclonal Cells product is a pooled population of human A-549 lung epithelial adenocarcinoma cells engineered via CRISPR/Cas9 to target the ARIH2 gene for disruption. By employing a polyclonal strategy, this knockout model preserves the diversity of editing events across the cell pool, avoiding the limitations of single-cell clonal expansion and providing a biologically relevant system for functional studies. The cells are supplied as a live stock for immediate experimental use in advanced biomedical research.
Derived from the lung adenocarcinoma tissue of a 58-year-old male Caucasian patient, the A-549 parental line is a widely established model for type II alveolar epithelium and non-small cell lung cancer. These cells recapitulate critical aspects of adenocarcinoma pathology, including constitutive mTOR pathway activation, making them an ideal host for studying ARIH2-mediated translation control. The A-549 background thus provides a clinically relevant platform to dissect ubiquitin-dependent processes in a cancer setting.
ARIH2 is an E3 ubiquitin ligase that catalyzes the ubiquitination of 4E-BP1 (EIF4EBP1), leading to its proteasomal degradation and derepression of eIF4E for cap-dependent translation. Its activity is regulated by mTORC1 signaling and cellular stress, positioning ARIH2 at a nexus between nutrient sensing and protein synthesis. ARIH2 functions within multi-protein complexes containing CUL2, CUL5, neddylated cullins, and E2 conjugating enzymes. Disruption of ARIH2 thus stabilizes 4E-BP1, inhibiting translation initiation and providing a powerful tool to dissect ubiquitin-proteasome pathway dynamics.
Within the A-549 lung adenocarcinoma model, ARIH2 knockout polyclonal cells enable dissection of the role of 4E-BP1 degradation in sustaining cap-dependent translation during oncogenic growth. Given the prevalent mTOR pathway overactivation in lung cancer, this system is instrumental for exploring the interplay between translation regulation and ubiquitination. Moreover, it facilitates testing of proteasome inhibitor combinations, offering a preclinical framework for evaluating therapeutic strategies that target protein homeostasis.
Typical applications include ubiquitination and degradation assays, translation regulation studies, cancer cell biology, and high-throughput screening. Assays such as Western blotting for 4E-BP1 and ubiquitin, RT-qPCR, proteasome activity measurements, polysome profiling, and cap-dependent translation reporter assays are well-suited to elucidate ARIH2 function. These polyclonal knockout cells are also amenable to genetic complementation, drug response profiling, and mechanistic studies of the mTOR-4E-BP1 axis. For further details on batch characteristics or technical assistance, please contact Ascent Research.
